AbbVie’s Immunology Growth Strategy Is Delivering, But Imbruvica Reduced By IRA

 
• By Joseph Haas
  
Writeoff
AbbVie has written down Imbruvica's value by $2.1bn • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business